ReviewNature reviews. Nephrology2024
Immune mechanisms in the pathophysiology of hypertension.
Review in Nature reviews. Nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Monocyte Activation Drives Atrial Fibrillation in Hypertension.Cardiovascular drugs and therapy · 2026Article
- Mineralocorticoid Receptor Blockade Mitigates Loop Diuretic-Exacerbated Plasma Volume Contraction and Target-Organ Fibrosis in Angiotensin II-Induced Hypertension.International journal of molecular sciences · 2026Article
- The Mechano-Immune-Vascular Activation Loop: An Integrative Conceptual Framework for Positive Feedback in Hypertension.International journal of molecular sciences · 2026Review
- Comparison of Novel Systemic Inflammatory Indices for Identification of Left Ventricular Hypertrophy in Hypertensive Patients: A Large-Scale Cross-Sectional Study in China.Journal of cardiovascular development and disease · 2026Article
- Unveiling the Immune Mechanisms of Hypertension With Single-Cell Transcriptome-Wide Mendelian Randomization.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Hypertensive mt. tRNARedox biology · 2026Article
- Effect of relative handgrip strength and back muscle strength on the incidence of hypertension: 18-year follow-up in a population-based cohort study.Journal of human hypertension · 2026Article
- Development and independent validation of a hypoxemia risk prediction model (HAPPY-12K) for sedated gastrointestinal endoscopy: a multicentre prospective cohort study.EClinicalMedicine · 2026Article
- Salt and chronic kidney disease.Nature reviews. Nephrology · 2026Review
- The Ketogenic Diet in the Prevention and Treatment of Hypertension (HTN).Biomedicines · 2026Review
- B1a Cell-IgM Axis Protects Against Hypertension by Blunting IFNγ+CD4+T Cells.Circulation research · 2026Article
- Review
- Gastrodin Ameliorates Blood Pressure by Targeting the PPAR-γ/NF-κB/NLRP3 Signaling Axis in the Hypothalamic Paraventricular Nucleus.Cardiovascular toxicology · 2026Article
- The Research Progress in Targeted Therapy for Hypertension via Heat Shock Proteins.International journal of molecular sciences · 2026Review
- Myeloid cell renin-angiotensin-aldosterone system in hypertension and inflammation.Current opinion in physiology · 2026Article
- Molecular systems, human noncoding sequence variants, and blood pressure.Physiological reviews · 2026Review
- Association between systemic immune-inflammation index and systemic inflammation response index and in-stent restenosis in patients with hypertension complicated by coronary heart disease.BMC cardiovascular disorders · 2026Article
- Systemic immune-inflammation index: a novel tool for hypertension management in primary care.BMC primary care · 2026Article
- Treatment Paradigm Shifts in Pulmonary Arterial Hypertension: Evidence From Asia on Vasodilators to Antiremodeling Therapies.JACC. Asia · 2026Article
- Innate immune profiling reveals a specific reduction of CD57Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Hypertension is a leading risk factor for morbidity and mortality worldwide. Despite current anti-hypertensive therapies, most individuals with hypertension fail to achieve adequate blood pressure control. Moreover, even with adequate control, a residual risk of cardiovascular events and associated organ damage remains. These findings suggest that current treatment modalities are not addressing a key element of the underlying pathology. Emerging evidence implicates immune cells as key mediators in the development and progression of hypertension. In this Review, we discuss our current understanding of the diverse roles of innate and adaptive immune cells in hypertension, highlighting key findings from human and rodent studies. We explore mechanisms by which these immune cells promote hypertensive pathophysiology, shedding light on their multifaceted involvement. In addition, we highlight advances in our understanding of autoimmunity, HIV and immune checkpoints that provide valuable insight into mechanisms of chronic and dysregulated inflammation in hypertension.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.